Jeffrey Weitz, MD

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

The FDA has approved dalteparin for extended treatment of venous thromboembolism for patients with cancer.